127 related articles for article (PubMed ID: 37967235)
1. Signs of Glucagon Resistance After a 2-Week Hypercaloric Diet Intervention.
Suppli MP; Høgedal A; Bagger JI; Chabanova E; van Hall G; Forman JL; Christensen MB; Albrechtsen NJW; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2024 Mar; 109(4):955-967. PubMed ID: 37967235
[TBL] [Abstract][Full Text] [Related]
2. Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis.
Winther-Sørensen M; Galsgaard KD; Santos A; Trammell SAJ; Sulek K; Kuhre RE; Pedersen J; Andersen DB; Hassing AS; Dall M; Treebak JT; Gillum MP; Torekov SS; Windeløv JA; Hunt JE; Kjeldsen SAS; Jepsen SL; Vasilopoulou CG; Knop FK; Ørskov C; Werge MP; Bisgaard HC; Eriksen PL; Vilstrup H; Gluud LL; Holst JJ; Wewer Albrechtsen NJ
Mol Metab; 2020 Dec; 42():101080. PubMed ID: 32937194
[TBL] [Abstract][Full Text] [Related]
3. The Liver-α-Cell Axis and Type 2 Diabetes.
Wewer Albrechtsen NJ; Pedersen J; Galsgaard KD; Winther-Sørensen M; Suppli MP; Janah L; Gromada J; Vilstrup H; Knop FK; Holst JJ
Endocr Rev; 2019 Oct; 40(5):1353-1366. PubMed ID: 30920583
[TBL] [Abstract][Full Text] [Related]
4. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis.
Suppli MP; Bagger JI; Lund A; Demant M; van Hall G; Strandberg C; Kønig MJ; Rigbolt K; Langhoff JL; Wewer Albrechtsen NJ; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2020 Jun; 69(6):1090-1099. PubMed ID: 31974144
[TBL] [Abstract][Full Text] [Related]
5. Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
Wewer Albrechtsen NJ; Junker AE; Christensen M; Hædersdal S; Wibrand F; Lund AM; Galsgaard KD; Holst JJ; Knop FK; Vilsbøll T
Am J Physiol Gastrointest Liver Physiol; 2018 Jan; 314(1):G91-G96. PubMed ID: 28971838
[TBL] [Abstract][Full Text] [Related]
6. Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids.
Wewer Albrechtsen NJ; Færch K; Jensen TM; Witte DR; Pedersen J; Mahendran Y; Jonsson AE; Galsgaard KD; Winther-Sørensen M; Torekov SS; Lauritzen T; Pedersen O; Knop FK; Hansen T; Jørgensen ME; Vistisen D; Holst JJ
Diabetologia; 2018 Mar; 61(3):671-680. PubMed ID: 29305624
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
Singh V; Grötzinger C; Nowak KW; Zacharias S; Göncz E; Pless G; Sauer IM; Eichhorn I; Pfeiffer-Guglielmi B; Hamprecht B; Wiedenmann B; Plöckinger U; Strowski MZ
Endocrinology; 2007 Aug; 148(8):3887-99. PubMed ID: 17525126
[TBL] [Abstract][Full Text] [Related]
8. Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease.
Maruszczak K; Radzikowski K; Schütz S; Mangge H; Bergsten P; Forslund A; Manell H; Pixner T; Ahlström H; Kullberg J; Mörwald K; Weghuber D
Front Endocrinol (Lausanne); 2022; 13():1004128. PubMed ID: 36133310
[TBL] [Abstract][Full Text] [Related]
9. The Liver-α-Cell Axis in Health and in Disease.
Richter MM; Galsgaard KD; Elmelund E; Knop FK; Suppli MP; Holst JJ; Winther-Sørensen M; Kjeldsen SAS; Wewer Albrechtsen NJ
Diabetes; 2022 Sep; 71(9):1852-1861. PubMed ID: 35657688
[TBL] [Abstract][Full Text] [Related]
10. Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.
Dutour A; Abdesselam I; Ancel P; Kober F; Mrad G; Darmon P; Ronsin O; Pradel V; Lesavre N; Martin JC; Jacquier A; Lefur Y; Bernard M; Gaborit B
Diabetes Obes Metab; 2016 Sep; 18(9):882-91. PubMed ID: 27106272
[TBL] [Abstract][Full Text] [Related]
11. The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease.
Winther-Sørensen M; Holst JJ; Wewer Albrechtsen NJ
Curr Opin Lipidol; 2023 Feb; 34(1):27-31. PubMed ID: 36373738
[TBL] [Abstract][Full Text] [Related]
12. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans.
Roden M; Perseghin G; Petersen KF; Hwang JH; Cline GW; Gerow K; Rothman DL; Shulman GI
J Clin Invest; 1996 Feb; 97(3):642-8. PubMed ID: 8609218
[TBL] [Abstract][Full Text] [Related]
13. Evidence of hepatic glucagon resistance associated with hepatic steatosis: reversal effect of training.
Charbonneau A; Couturier K; Gauthier MS; Lavoie JM
Int J Sports Med; 2005; 26(6):432-41. PubMed ID: 16037884
[TBL] [Abstract][Full Text] [Related]
14. Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis.
Beaulant A; Dia M; Pillot B; Chauvin MA; Ji-Cao J; Durand C; Bendridi N; Chanon S; Vieille-Marchiset A; Da Silva CC; Patouraux S; Anty R; Iannelli A; Tran A; Gual P; Vidal H; Gomez L; Paillard M; Rieusset J
J Hepatol; 2022 Sep; 77(3):710-722. PubMed ID: 35358616
[TBL] [Abstract][Full Text] [Related]
15. High-fat diet-induced hepatic steatosis reduces glucagon receptor content in rat hepatocytes: potential interaction with acute exercise.
Charbonneau A; Unson CG; Lavoie JM
J Physiol; 2007 Feb; 579(Pt 1):255-67. PubMed ID: 17053032
[TBL] [Abstract][Full Text] [Related]
16. Glucagon and Liver Fat are Downregulated in Response to Very Low-calorie Diet in Patients with Obesity and Type-2 Diabetes.
Haas SL; Löfgren P; Stål P; Hoffstedt J
Exp Clin Endocrinol Diabetes; 2022 Jan; 130(1):55-60. PubMed ID: 32767285
[TBL] [Abstract][Full Text] [Related]
17. A Primary Role for α-Cells as Amino Acid Sensors.
Dean ED
Diabetes; 2020 Apr; 69(4):542-549. PubMed ID: 31653720
[TBL] [Abstract][Full Text] [Related]
18. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial.
Koopman KE; Caan MW; Nederveen AJ; Pels A; Ackermans MT; Fliers E; la Fleur SE; Serlie MJ
Hepatology; 2014 Aug; 60(2):545-53. PubMed ID: 24668862
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic Fatty Liver Disease Impairs the Liver-Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis.
Pedersen JS; Rygg MO; Kristiansen VB; Olsen BH; Serizawa RR; Holst JJ; Madsbad S; Gluud LL; Bendtsen F; Wewer Albrechtsen NJ
Hepatol Commun; 2020 Nov; 4(11):1610-1623. PubMed ID: 33163832
[TBL] [Abstract][Full Text] [Related]
20. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
